Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11065022 | 1.00 | PNMT (0.49) | PNMTMEN1ALDH1A1CYP1A2POLB | |
| SCHEMBL172624 | 0.87 | TAS1R3 (0.48) | PNMTMEN1ALDH1A1CYP1A2POLB | |
| SCHEMBL11407610 | 0.85 | PNMT (0.47) | PNMTMEN1ALDH1A1CYP1A2POLB | |
| SCHEMBL10217243 | 0.85 | PNMT (0.51) | PNMTMEN1ALDH1A1CYP1A2POLB | |
| SCHEMBL18252839 | 0.85 | PNMT (0.47) | PNMTMEN1ALDH1A1CYP1A2POLB | |
| SCHEMBL28220660 | 0.85 | HTR2A (0.54) | PNMTMEN1ALDH1A1CYP1A2POLB | |
| SCHEMBL19443029 | 0.85 | PNMT (0.51) | PNMTMEN1ALDH1A1CYP1A2POLB | |
| SCHEMBL14262202 | 0.85 | PNMT (0.51) | PNMTMEN1ALDH1A1CYP1A2POLB | |
| Hydrochloric Acid SCHEMBL19244848 | 0.84 | PNMT (0.50) | PNMTMEN1ALDH1A1CYP1A2POLB | |
| SCHEMBL18593504 | 0.83 | PNMT (0.45) | PNMTMEN1POLBKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3297438-B1 | CCR2 MODULATORS | CHEMOCENTRYX INC (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2020-04-23 | — | — | US | disclosed |
| WO-2019136368-A2 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| WO-2019060820-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160340356-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | PNMT 2379/4885MEN1 4868/4885ALDH1A1 1316/4885 |
| US-20160340356-A1 | CCR2 MODULATORS | CCR2, CCR1, CCR5 | PNMT 3762/4885MEN1 4866/4885ALDH1A1 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.